Tuesday, January 03, 2023 7:59:43 AM
Recent HOOK News
- HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV • GlobeNewswire Inc. • 07/01/2024 08:31:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:15:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:15:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:15:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:15:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/18/2024 08:03:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 08:15:13 PM
- HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting • GlobeNewswire Inc. • 06/04/2024 05:00:44 PM
- HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting • GlobeNewswire Inc. • 05/30/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 09:05:13 PM
- HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting • GlobeNewswire Inc. • 05/23/2024 09:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 11:04:49 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 11:03:13 AM
- HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 05/09/2024 11:01:00 AM
- HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab • GlobeNewswire Inc. • 04/25/2024 11:01:00 AM
- HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers • GlobeNewswire Inc. • 04/24/2024 11:01:00 AM
- HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/16/2024 08:30:00 PM
- HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration • GlobeNewswire Inc. • 04/10/2024 11:01:00 AM
- HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 03/22/2024 11:01:00 AM
- HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference • GlobeNewswire Inc. • 03/06/2024 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 09:30:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 01:12:08 PM
- HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs • GlobeNewswire Inc. • 01/29/2024 01:01:00 PM
- HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization • GlobeNewswire Inc. • 01/16/2024 12:01:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/05/2024 05:15:14 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM